We are live on ! Find out more
MVM

Medicxi Ventures Management Portfolio holdings

AUM $982M
1-Year Est. Return 210.17%
This Fund
S&P 500
This Quarter Est. Return
+3.54%
1 Year Est. Return
+210.17%
3 Year Est. Return
+787.54%
5 Year Est. Return
+404.19%
10 Year Est. Return
AUM
$233M
AUM Growth
-$4.72M
Cap. Flow
$0
Cap. Flow %
0%
Top 10 Hldgs %
100%
Holding
6
New
Increased
Reduced
Closed

Top Buys

No buys this quarter

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CNTA
1
DELISTED
Centessa Pharmaceuticals
CNTA
$76.9M 32.93%
19,963,157
PCVX icon
2
Vaxcyte
PCVX
$7.81B
$54.6M 23.4%
1,457,300
MRUS
3
DELISTED
Merus
MRUS
$29.4M 12.61%
1,600,000
AURA icon
4
Aura Biosciences
AURA
$725M
$28.2M 12.09%
3,039,892
NAMS icon
5
NewAmsterdam Pharma
NAMS
$3.25B
$26.5M 11.36%
2,000,000
PHAT icon
6
Phathom Pharmaceuticals
PHAT
$708M
$17.7M 7.6%
2,484,274

Similar funds

Medicxi Ventures Management's Q1 2023 Portfolio in Review

As of Q1 2023, Medicxi Ventures Management held 6 positions worth $233M, down 2% from $238M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q1 2023: portfolio turnover was 0%. Medicxi Ventures Management opened no new positions and made no exits, leaving the 6-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Medicxi Ventures Management's ten largest holdings make up 100% of its $233M portfolio in Q1 2023.
  • Medicxi Ventures Management opened 0 new positions and closed 0 in Q1 2023.
  • Medicxi Ventures Management's portfolio value fell 2% quarter-over-quarter to $233M.

Based on Medicxi Ventures Management's 13F filing for Q1 2023, filed 27 Apr 2023.